Yu Xia bought $10.0M of Summit Therapeutics (SMMT)
Executed Oct 21 2025, disclosed Oct 24 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 23 2025), the stock returned -13.7% (delay-adjusted); from the execution session (Oct 21 2025), -15.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Yu Xia (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Summit Therapeutics Inc. (SMMT). Across 1 priced purchase filing, the average 21-session return was -15.9% from execution and -13.7% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of SMMT (533,617 sh × $18.74, as filed), executed Oct 21 2025.
Healthcare · Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, care…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→